Navigation Links
INTERMACS: Total Artificial Heart Bridge-to-Transplant Rate 2x Higher ,at 6 Months Than BiVADS and LVADs
Date:5/12/2009

Replacing Both Ventricles with the Total Artificial Heart Eliminates Complications Including Right Heart Failure

Tucson, Ariz. (Vocus) May 12, 2009 -- According to INTERMACS data recently published in SynCardia’s 2008 Annual Report, the SynCardia temporary CardioWest™ Total Artificial Heart has a bridge-to-transplant rate of 72% at 6 months. This is double the bridge-to-transplant rate for Biventricular Assist Devices (BiVADS) at 36% and Left Ventricular Assist Devices (LVADs) at 27% (see Chart 1).

Unlike BiVADs and LVADs which assist the heart ventricle(s), the Total Artificial Heart replaces both dying heart ventricles. This eliminates complications caused by a dying heart including right native heart failure.

According to INTERMACS, 8% of BiVAD patients and 10% of LVAD patients experience right heart failure (see Chart 2). These patients often require treatment with inotropes and/or implantation of a right ventricular assist device. Total Artificial Heart patients are not subject to right native heart failure because the dying heart ventricles have been removed.

INTERMACS is the US national registry for patients with mechanical circulatory support devices that treat advanced heart failure. By applying uniform definitions and standards, INTERMACS levels the playing field for all mechanical circulatory support devices. INTERMACS tracks patient survival, adverse events and cause of death over time by patient profile, device and device category.

INTERMACS was created as a joint effort of the National Heart, Lung and Blood Institute (NHLBI), the Centers for Medicare and Medicaid Services (CMS), the Food and Drug Administration (FDA) and the United Network for Organ Sharing (UNOS) among others.

Originally designed as a permanent replacement heart, the Total Artificial Heart is currently approved as a bridge to human heart transplant for patients dying from end-stage biventricular failure. The Total Artificial Heart is the only device that provides immediate, safe blood flow of up to 9.5 L/min through both ventricles.

The SynCardia Total Artificial Heart is the first and only FDA, Health Canada and CE Mark approved Total Artificial Heart in the world. There have been more than 790 implants of the Total Artificial Heart, accounting for more than 160 patient years of life on the device.

###

Read the full story at http://www.prweb.com/releases/2009/05/prweb2404984.htm.


'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved  

Related medicine news :

1. Total Artificial Heart Patient 3rd in the World to Receive Dual Transplants
2. Extra payments to Medicare Advantage plans to total $11.4 billion in 2009
3. Swine Flu Cases Now Total 7: CDC
4. NuVasive Announces Acquisition of Cervical Total Disc Replacement Device
5. SynCardia Introduces New 12-lb Freedom Discharge Driver Designed to Provide Quality 'Lifestyle' for Total Artificial Heart Patients
6. Squeezing Calories? New Study Finds That Low-Fat Popcorn Before Lunch Does Not Increase Total Calorie Intake
7. FCP Announces Total Healthcare Integration Solution (THIS) Powered by TIBCO
8. Closing Open Heart Surgery: Saint Josephs Performs Georgias First Totally-Closed, Beating Heart Bypass Surgery
9. Hip Resurfacing Championed as a Bone-Preserving Alternative to Total Hip Replacement
10. MEDRAD Multi Vendor Service Launches TotalRepair(SM) on Select Ultrasound Probes
11. Highline Data Analysis Shows Year-over-Year P&C Industry Net Income Down 67.7%, Life Industry Net Unrealized Capital Losses Totaled $51.7 billion in 2008
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
INTERMACS: Total Artificial Heart Bridge-to-Transplant Rate 2x Higher ,at 6 Months Than BiVADS and LVADs
(Date:6/25/2016)... ... ... Bruton Memorial Library on June 21 due to a possible lice infestation, as reported by ... lice: the parasite’s ability to live away from a human host, and to infest common ... the event that lice have simply gotten out of control. , As lice are a ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, Dr. ... his M.D from the David Geffen School of Medicine at UCLA. He trained in ... to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he ...
(Date:6/25/2016)... Montreal, Canada (PRWEB) , ... June 25, 2016 , ... ... the pursuit of success. In terms of the latter, setting the bar too high ... low, risk more than just slow progress toward their goal. , Research from ...
(Date:6/24/2016)... ... 2016 , ... June 19, 2016 is World Sickle Cell Observance Day. In ... benefits of holistic treatments, Serenity Recovery Center of Marne, Michigan, has issued ... Sickle Cell Disease (SCD) is a disorder of the red blood cells, which can ...
(Date:6/24/2016)... Fla. (PRWEB) , ... June 24, 2016 , ... Global ... Trend magazine’s 2016 Legal Elite. The attorneys chosen by their peers for this recognition ... Florida. , Seven Greenberg Traurig Shareholders received special honors as members of this year’s ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... , June 24, 2016 ... Market by Type (Standard Pen Needles, Safety Pen Needles), ... (Insulin, GLP-1, Growth Hormone), Mode of Purchase (Retail, Non-Retail) ... MarketsandMarkets, This report studies the market for the forecast ... to reach USD 2.81 Billion by 2021 from USD ...
(Date:6/24/2016)... 24, 2016  Arkis BioSciences, a leading innovator ... more durable cerebrospinal fluid treatments, today announced it ... funding is led by Innova Memphis, followed by ... private investors.  Arkis, new financing will accelerate the ... market release of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... -- Any dentist who has made an implant supported denture ... of them do not even offer this as a viable ... costs involved. And those who ARE able to offer that ... cost that the majority of today,s patients would not be ... , founder of Dental Evolutions Inc. and inventor of Implanova ...
Breaking Medicine Technology: